Autobahn News

Autobahn Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences

Autobahn Therapeutics to Participate in Evercore’s Emerging Private Biotech Conference

Autobahn Therapeutics to Participate in Jefferies Global Healthcare Conference

Autobahn Therapeutics Announces Presentation of ABX-002 Phase 1 Clinical Results at the 2025 ASCP Annual Meeting

Autobahn Therapeutics Announces Initiation of Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Bipolar Depression

Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences

Autobahn Therapeutics Announces FDA Clearance of IND Application for ABX-002 as an Adjunctive Treatment for Bipolar Depression

Autobahn Therapeutics Announces Initiation of its AMPLIFY Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Major Depressive Disorder

Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences

Autobahn Therapeutics Completes Oversubscribed $100 Million Series C Financing to Advance Pipeline of Novel Therapeutics for Depression and Other CNS Disorders

Autobahn Therapeutics to Participate in the Leerink Partners Biopharma Private Company Connect

Autobahn Therapeutics to Participate in the Jefferies Global Healthcare Conference

Autobahn Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

Autobahn Therapeutics to Present at the Stifel 2024 Virtual CNS Days

Autobahn Therapeutics to Participate in Upcoming Investor Conferences

Autobahn Therapeutics to Present at the Stifel 2023 Healthcare Conference

Autobahn Therapeutics Announces Positive Topline Results from Phase 1 Study of ABX-002, its Lead Oral Treatment for Major Depressive Disorder

Autobahn Therapeutics to Present at Upcoming Investor Conferences

Autobahn Therapeutics Completes Dosing in its Phase 1 Multiple-ascending Dose Study of ABX-002 for Major Depressive Disorder and Reports Company Progress

Autobahn Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Autobahn Therapeutics Advances ABX-002, its Lead Oral Treatment for Major Depressive Disorder, into Multi-Ascending Dose Portion of Phase 1 Trial

Autobahn Therapeutics to Present at the Stifel 2023 Virtual CNS Days

Autobahn Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ABX-002 for the Treatment for Major Depressive Disorder

Autobahn Therapeutics Announces Successful Financing to Support Strategic Advancement of ABX-002 for Treatment Resistant Depression

Autobahn Therapeutics Announces Emerging Preclinical Data Demonstrating Ability of CNS-Delivered Thyromimetics to Promote Remyelination

Autobahn Therapeutics to Present New Preclinical Data at the 2022 American Academy of Neurology Annual Meeting

Autobahn Therapeutics Announces New Preclinical Data Supporting its Novel Brain-Targeting Platform for the Development of Therapeutics for CNS Disorders

Autobahn Therapeutics Strengthens Management Team to Support Advancement of Novel Therapies for CNS Disorders

Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas, Strengthening its Brain Targeting Chemistry Platform

Autobahn Therapeutics Presents Preclinical, Proof of Concept Data for ABX-002 for the Treatment of Adrenomyeloneuropathy

Autobahn Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

ARCH-backed Autobahn launches with $76M to rebuild myelin and reverse MS

Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders